Low-cost anti-mycobacterial drug discovery using engineered E. coli.

MLA

Bongaerts, Nadine, et al. “Low-Cost Anti-Mycobacterial Drug Discovery Using Engineered E. Coli.” Nature Communications, vol. 13, no. 1, July 2022, p. 3905. EBSCOhost, https://doi.org/10.1038/s41467-022-31570-3.

APA

Bongaerts, N., Edoo, Z., Abukar, A. A., Song, X., Sosa-Carrillo, S., Haggenmueller, S., Savigny, J., Gontier, S., Lindner, A. B., & Wintermute, E. H. (2022). Low-cost anti-mycobacterial drug discovery using engineered E. coli. Nature Communications, 13(1), 3905. https://doi.org/10.1038/s41467-022-31570-3

Chicago

Bongaerts, Nadine, Zainab Edoo, Ayan A Abukar, Xiaohu Song, Sebastián Sosa-Carrillo, Sarah Haggenmueller, Juline Savigny, Sophie Gontier, Ariel B Lindner, and Edwin H Wintermute. 2022. “Low-Cost Anti-Mycobacterial Drug Discovery Using Engineered E. Coli.” Nature Communications 13 (1): 3905. doi:10.1038/s41467-022-31570-3.